We’re Making History!

Over 30 years of delivering early intervention orthopedic products that help Restore Active Living for people around the world

Explore some of Anika’s Milestones:

Anika History

2025

Completed divestiture of Parcus Medical to Medacta International

2024

Commenced full market release of the Integrity™ Implant System, a regenerative hyaluronic acid-based scaffold for tendon repair, along with its complete arthroscopic instrumentation platform for rotator cuff repair.

Completed the divestiture of its Arthrosurface business to Phoenix Brio, Incorporated.

2023

Received 510(k) clearance then commenced limited market release after performing first surgeries using the Integrity Implant System.

Completed enrollment in Hyalofast^® pivotal Phase III clinical study, a key milestone in its path to achieving US FDA approval.

Tactoset^® received additional FDA 510(k) clearance to be combined with autogenous bone marrow aspirate (BMA).

2022

Received the ACE Award for cutting-edge innovation from the American Orthopedic Society for Sports Medicine (AOSSM) for Tactoset Injectable Bone Substitute for hardware augmentation.

Cingal^® successfully achieved its primary endpoint in its third Phase III clinical trial.

2021

FDA 510(k) clearance received for Tactoset Injectable Bone Substitute to include a new indication for augmentation of hardware, including suture anchors.

Competed enrollment for US pilot clinical study of Cingal, a combination hyaluronic acid (HA) and fast-acting steroid injection for osteoarthritis knee pain.

2020

Anika acquired Arthrosurface, a leading, privately-held provider of joint preservation solutions, and Parcus Medical, a leading, privately-held sports medicine company.

Cheryl R. Blanchard, Ph.D., appointed as President and Chief Executive Officer.

2019

Tactoset, a surgically delivered therapy for insufficiency fractures, was launched in the United States.

2018

Monovisc^® and Orthovisc^® became the #1 prescribed viscosupplement franchise in the United States.

2017

FDA 510(k) clearance received for HA-enhanced Tactoset Injectable Bone Substitute for the treatment of insufficiency fractures.

2016

International launch of Cingal, the first HA-based viscosupplement plus steroid combination product for the treatment of osteoarthritis pain.

CE Mark approval received for Orthovisc^®-T, a treatment designed to relieve pain and restore function for patients with chronic tennis elbow.

2015

A larger 5x5cm Hyalofast^® scaffold to treat large cartilage defects was introduced internationally.

2014

FDA approval and launch of Monovisc, the first non-animal sourced hyaluronic acid single-injection treatment for knee osteoarthritis in the United States.

2012

Orthovisc achieved #1 U.S. market leader position in the multi-injection viscosupplement market.

First procedure performed using NanoFx^®, an improved microfracture solution compared to the standard marrow-based regenerative technique¹.

2009

Acquired technology used in Hyalofast, a one-step cartilage regeneration product, through the strategic acquisition of Fidia Advanced Biopolymers, a leading innovator in hyaluronic acid-based tissue engineered products, based in Abano Terme, Italy.

Hyalofast received CE mark approval and launched internationally.

2007

CE mark approval received for Monovisc in Europe.

2004

Obtained FDA approval for and launched Orthovisc in the United States.

2003

Established a marketing and distribution relationship with Johnson & Johnson to sell Orthovisc in the United States once approved by the FDA.

1996

Received CE mark approval for and launched Orthovisc internationally, the company’s first HA-based viscosupplement used for the treatment of osteoarthritis pain.

1995

Signed a distribution agreement with Boehringer Ingelheim Vetmedica for its HA-based equine osteoarthritis product, Hyvisc^®, a partnership that has continued to this day.

1992

Anika Therapeutics was incorporated as a spin-off of MedChem Products, Inc.

Signed an agreement with Johnson & Johnson to manufacture and supply its hyaluronic acid-based ophthalmic products, Amvisc^® and Amvisc^® Plus.